D&A at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s D&A?
- ARS Pharmaceuticals, Inc. (SPRY) reported D&A of $397K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s D&A changed year-over-year?
- ARS Pharmaceuticals, Inc.'s D&A increased by 41.8% year-over-year, from $280K to $397K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s D&A?
- Over 2 years (2023 to 2025), ARS Pharmaceuticals, Inc.'s D&A has grown at a 332.7% compound annual growth rate (CAGR), from $73K to $1.37M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.